EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Imeglimin improves hyperglycemia and hypoglycemia‐induced cell death and mitochondrial dysfunction in immortalized adult mouse Schwann IMS32 cells

Ayako Kato iD, Wataru Nihei, Hideji Yako, Yasuaki Tatsumi, Tatsuhito Himeno, Masaki Kondo iD, Yoshiro Kato, Jiro Nakamura iD, Hideki Kamiya iD, Kazunori Sango iD, Koichi Kato iD

Journal of Diabetes Investigation · 2025

DOI: 10.1111/jdi.70092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes Investigation, 2025. Verfasst von Ayako Kato und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Medicine, Aichi Gakuin University School of Pharmacy, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Schwann Cells, Mitochondria, Hyperglycemia, Cell Death. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Introduction Imeglimin, a novel oral antidiabetic drug, enhances glucose‐stimulated insulin secretion, improves insulin sensitivity, and reduces mitochondrial reactive oxygen species (ROS) generation. Diabetic neuropathy is driven by oxidative stress caused by hyperglycemia, with mitochondrial ROS overproduction playing a central role. Hypoglycemia also contributes to oxidative stress. This study evaluates the effects of imeglimin on Schwann cells under high‐ and low‐glucose conditions. Materials and Methods We used IMS32 cells, an immortalized mouse Schwann cell line, to investigate cell survival and mitochondrial function under normal, high‐, and low‐glucose conditions. Assessments included mitochondrial oxidative stress, cytochrome c release, mitochondrial membrane potential, oxygen consumption rate (OCR), Complex I activity, and ATP synthesis.

Results

High‐ and low‐glucose conditions caused cell death, elevated mitochondrial ROS, triggered cytochrome c release, disrupted mitochondrial membrane potential, and increased OCR and Complex I activity, while suppressing ATP synthesis. Imeglimin treatment mitigated cell death, reduced oxidative stress, restored mitochondrial membrane potential, normalized OCR and Complex I activity, and improved ATP synthesis under both glucose conditions.

Conclusions

Fluctuations in glucose levels impair mitochondrial function in Schwann cells, contributing to peripheral nerve damage in diabetic neuropathy. Imeglimin demonstrated protective effects by alleviating mitochondrial dysfunction and preventing apoptosis signaling. These findings suggest the potential application of imeglimin in preventing and treating diabetic neuropathy; however, the clinical implications require further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Schwann CellsMitochondriaHyperglycemiaCell DeathHypoglycemiaHypoglycemic AgentsAnimalsMiceOxidative StressMembrane Potential, MitochondrialReactive Oxygen SpeciesGlucoseCell LineOligopeptides

Stichwörter der Autor:innen

Diabetic neuropathyMitochondriaSchwann cells

Substanzen

arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamideReactive Oxygen SpeciesGlucoseHypoglycemic AgentsOligopeptides

Autor:innen und Institutionen

  • Laboratory of Medicine, Aichi Gakuin University School of Pharmacy, Nagoya, Aichi, Japan.
  • Diabetic Neuropathy Project, Department of Sensory and Motor Systems, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
  • Laboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy & Life Science, Hachioji, Tokyo, Japan.
  • Laboratory of Medical Biochemistry, Toho University School of Pharmacy, Funabashi, Chiba, Japan.
  • Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.

ORCID-Profile: Ayako Kato, Masaki Kondo, Jiro Nakamura, Hideki Kamiya, Kazunori Sango, Koichi Kato

Zitieren

APA

Kato, A., Nihei, W., Yako, H., Tatsumi, Y., Himeno, T., Kondo, M., Kato, Y., Nakamura, J., Kamiya, H., Sango, K., & Kato, K. (2025). Imeglimin improves hyperglycemia and hypoglycemia‐induced cell death and mitochondrial dysfunction in immortalized adult mouse Schwann IMS32 cells. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.70092

Vancouver

Kato A, Nihei W, Yako H, Tatsumi Y, Himeno T, Kondo M, et al. Imeglimin improves hyperglycemia and hypoglycemia‐induced cell death and mitochondrial dysfunction in immortalized adult mouse Schwann IMS32 cells. Journal of Diabetes Investigation. 2025. doi:10.1111/jdi.70092

BibTeX
@article{Kato2025,
  author = {Kato, Ayako and Nihei, Wataru and Yako, Hideji and Tatsumi, Yasuaki and Himeno, Tatsuhito and Kondo, Masaki and Kato, Yoshiro and Nakamura, Jiro and Kamiya, Hideki and Sango, Kazunori and Kato, Koichi},
  title = {Imeglimin improves hyperglycemia and hypoglycemia‐induced cell death and mitochondrial dysfunction in immortalized adult mouse Schwann IMS32 cells},
  journal = {Journal of Diabetes Investigation},
  year = {2025},
  doi = {10.1111/jdi.70092}
}
Kostenlos starten →